Journal of Gastroenterology

, Volume 31, Issue 6, pp 806–811

Expression of interferon-alpha receptor mRNA in the liver in chronic liver diseases associated with hepatitis C virus: Relation to effectiveness of interferon therapy

  • Ryo Fukuda
  • Norihisa Ishimura
  • Shunji Ishihara
  • Alejandro Tokuda
  • Shuichi Satoh
  • Shino Sakai
  • Shuji Akagi
  • Makoto Watanabe
  • Shiro Fukumoto
Liver, Pancreas, and Biliary Tract

Abstract

To investigate whether interferon-alpha receptor (IFN-αRc) expression was related to the effectiveness of interferon therapy in hepatitis C virus (HCV)-associated chronic liver disease (CLD), IFN-αRc mRNA was investigated by reverse transcription polymerase chain reaction (RT-PCR) in liver biopsies and peripheral blood mononuclear cells (PBMCs) from 40 patients with HCV-associated CLD who subsequently received IFN-α therapy. IFN-αRc mRNA in the liver was detected in 18 of 20 (90%) responders to IFN and in 5 of 20 (25%) non-responders (P<0.01). In PBMCs, IFN-αRc mRNA was detected in all patients regardless of response to IFN. Increased histological hepatitis activity and liver fibrosis were significantly related to the absence of IFN-αRc mRNA. The HCV-RNA genotype showed no significant relationship to IFN-αRc mRNA expression. Our results suggest that IFN-αRc mRNA expression in the liver, but not in PBMCs, is closely associated with the effectiveness of IFN-α therapy in HCV-associated CLD.

Key words

Chronic hepatitis C interferon-α receptor mRNA interferon therapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Magrin S, Graxi A, Fabiano C, et al. Serum hepatitis C virus (HCV)-RNA and response to alpha interferon in anti-HCV positive chronic hepatitis. J Med Virol 1992;38:200–206.PubMedGoogle Scholar
  2. 2.
    Kanazawa Y, Hayashi N, Mita E, et al. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 1994;20:1121–1130.CrossRefPubMedGoogle Scholar
  3. 3.
    Yoshida K, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha: Relationship to genotype of hepatitis C virus. Hepatology 1992;14:35–40.Google Scholar
  4. 4.
    Weiland O, Schvarcz R, Weijstal R, et al. Therapy of chronic posttransfusion non-A non-B hepatitis with interferon alpha-2b: Swedish experience. J Hepatol 1990;11(Suppl 19):S57-S62.PubMedGoogle Scholar
  5. 5.
    Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994;19:1088–1094.CrossRefPubMedGoogle Scholar
  6. 6.
    Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334:77–81.CrossRefPubMedGoogle Scholar
  7. 7.
    Yonehara S, Yonehara-Takahashi M, Ishii A. Binding of human interferon alpha to cells of different sensitivities: Studies with internally radiolabeled interferon retaining full biological activity. J Virol 1983;45:1168–1171.PubMedGoogle Scholar
  8. 8.
    Zoon KC, Arnheimer H. Studies of the interferon receptors. Pharmacol Ther 1984;24:259–278.CrossRefPubMedGoogle Scholar
  9. 9.
    Kato T, Esumi M, Yamashita S, et al. Interferon-inducible gene expression in chimpanzee liver infected with hepatitis C virus. Virology 1992;190:856–860.CrossRefPubMedGoogle Scholar
  10. 10.
    Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein kinase in the interferon alpha/beta signaling pathway. Cell 1992;24:313–322.Google Scholar
  11. 11.
    De Maeyer E, De Maeyer-Guignand J. Interferon receptor. In: De Maeyere E, De Maeyer-Guignand J (eds) Interferon and other revelatory cytokines. New York: John Wiley and Sons, 1988;91–113.Google Scholar
  12. 12.
    Lau AS, Hanningan GE, Freedman MH, Williams BRG. Regulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy. J Clin Invest 1986; 77:1632–1638.PubMedGoogle Scholar
  13. 13.
    Gallo-Rayet N, Escher E. Adrenocorticotropin receptors in rat adrenal glomerulosa cells. Endocrinology 1985;117:38–46.Google Scholar
  14. 14.
    Merlin G, Falcoff E, Aguet M.125I-labeled human interferon alpha beta and gamma: Comparative receptor-binding data. J Gen Virol 1985;66:1149–1152.PubMedGoogle Scholar
  15. 15.
    Aguet M, Grobke M, Dreiding P. Various human interferon alpha subclasses cross-react with common receptors: Their binding affinities correlate with their specific biological activities. Virology 1984;132:211–216.CrossRefPubMedGoogle Scholar
  16. 16.
    De Maeyer E, De Maeyer-Guignand J. Production of IFN-γ by T cells and modulation of T cell, B cell, and NK cell activity by interferons. In: De Maeyere E, De Maeyer-Guignand J (eds) Interferon and other revelatory cytokines. New York: John Wiley and Sons, 1988;221–273.Google Scholar
  17. 17.
    Uzé G, Lutfalla G, Gresser I. Genetic transfer of a functional human interferon α receptor into mouse cells: Cloning and expression of its cDNA. Cell 1990;60:225–234.PubMedGoogle Scholar
  18. 18.
    Ishimura N, Fukuda R, Fukumoto S. Relationship between the expression of interferon-alpha receptor mRNA and the histological progress of hepatitis C virus-associated chronic liver diseases. J Gastroenterol Hepatol 1996;11:712–717.PubMedGoogle Scholar
  19. 19.
    Karino Y, Hige S, Sasaki Y, Tsuyuguchi M, Matsushima T, Miyazaki T, Okuuchi Y, Toyota J. Relationship between serum 2-5AS activity and the reduction of HCV-RNA during interferon therapy. In: Nishioka K, Suzuki H, Mishiro S, Oda K (eds). Viral hepatitis and liver disease. Tokyo New York Berlin Heidelberg: Springer, 1994;631–634.Google Scholar
  20. 20.
    Fukuda R, Satoh S, Nguyen TX, et al. Expression of cytokine mRNA in the liver of chronic hepatitis C: Comparison with chronic hepatitis B. J Gastroenterol 1995;31:41–47.Google Scholar
  21. 21.
    Okamoto H, Sugiyama Y, Okada S, et al. Typing of hepatitis C virus by polymerase chain reaction with type specific primers; application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73:673–679.PubMedGoogle Scholar
  22. 22.
    Hagiwara H, Hayashi N, Mita E, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. Gastroenterology 1993;104:877–883.PubMedGoogle Scholar
  23. 23.
    Degroote J, Desmet VJ, Gedigk P, et al. A classification of chronic hepatitis. Lancet 1968;II:626–628.Google Scholar
  24. 24.
    Knodell RG, Isak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431–435.PubMedGoogle Scholar
  25. 25.
    De Maeyer E, De Maeyer-Guignand J. The antiviral activity of interferon. In: De Maeyere E, De Maeyer-Guignand J (eds) Interferon and other revelatory cytokines. New York: John Wiley, Sons, 1988;115–133.Google Scholar
  26. 26.
    Su L, Morgan PR, Harrison DL, Waseen A, Lane EB. Expression of keratin mRNAs and proteins in normal salivary epithelia and pleomorphic adenomas. J Pathol 1993;171:173–181.CrossRefPubMedGoogle Scholar
  27. 27.
    Greenway AL, Hertzog PJ, Devenish RJ, et al. Immunolocalisation of interferon-alpha in hepatitis C patients and its correlation with response to interferon-alpha therapy. J Hepatol 1994;21:842–852.CrossRefPubMedGoogle Scholar
  28. 28.
    Müller U, Steihoff U, Reis LF, et al. Functional roles of type I and type II interferons in antiviral defense. Science 1994;264:1918–1921.PubMedGoogle Scholar
  29. 29.
    Branca AA, Bagloni C. Down-regulation of the interferon receptor. J Biol Chem 1982;257:13197–13200.PubMedGoogle Scholar
  30. 30.
    Evans T, Secher DD. Kinetics of internalization and degradation of surface-bound interferon in human lymphoblastoid cells. EMBO J 1984;3:2975–2978.PubMedGoogle Scholar
  31. 31.
    Novick D, Cohen B, Rubinstein M. The human interferon α/β receptor: Characterization and molecular cloning. Cell 1994; 77:391–400.CrossRefPubMedGoogle Scholar
  32. 32.
    Affabris E, Romeo G, Belardelli F, et al. 2-5A synthetase activity does not increase in interferon-resistant Friend leukemia cell variants treated with α/β interferon despite the presence of high-affinity interferon receptor sites. Virology 1983;125:508–512.CrossRefPubMedGoogle Scholar
  33. 33.
    Auguet M, Gresser I, Hovanessian AG, et al. Specific high-affinity binding of125I-labeled mouse interferon to interferon-resistant embryonal carcinoma cells in vitro. Virology 1981;114:585–588.Google Scholar
  34. 34.
    Klippel JH, Carrete S, Preble S, et al. Serum alpha interferon and lymphocyte inclusions in systemic lupus erythematosus. Ann Rheum Dis 1985;44:104–108.PubMedGoogle Scholar
  35. 35.
    Koziel MJ, Duddley D, Wong JT, et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992;149:3339–3344.PubMedGoogle Scholar
  36. 36.
    Kita H, Moriyama T, Kaneko T, et al. HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein. Hepatology 1993;18:1039–1044.CrossRefPubMedGoogle Scholar
  37. 37.
    Lörh HF, Schlaak JF, Gerken G, et al. Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different etiology. Liver 1994;14:161–166.Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • Ryo Fukuda
    • 1
  • Norihisa Ishimura
    • 1
  • Shunji Ishihara
    • 1
  • Alejandro Tokuda
    • 1
  • Shuichi Satoh
    • 1
  • Shino Sakai
    • 1
  • Shuji Akagi
    • 1
  • Makoto Watanabe
    • 1
  • Shiro Fukumoto
    • 1
  1. 1.Second Department of Internal MedicineShimane Medical UniversityShimaneJapan

Personalised recommendations